These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The inhibitory effects of Realgar bioleaching solution on S180 ascites-tumor and its toxicity].
    Author: Xie QJ, Zhang X, Wang X, Bai L, Li HY.
    Journal: Zhong Yao Cai; 2009 Jun; 32(6):933-6. PubMed ID: 19764334.
    Abstract:
    OBJECTIVE: To investigate the inhibitory effect of Realgar bioleaching solution (RBS) on tumor S180 cells line and estimate its toxicity, to provide experimental evidence for the further exploit of Realgar. METHODS: 24 hours after the models of ascites-tumor bearing mice were established, the mice were injected RBS once a day. The survival rates of S180 ascites-tumor bearing mice injected in RBS was studied, and the RBS acute toxicity of mice produced by oral, intraperitoneal or intravenous was evaluated by Drug Median Lethal Dose (LD50). RESULTS: The inhibitory effect of S180 cells in vivo had a dose-dependent manner. The survival rates of mice were 10% - 60% in the different dose in 15 days. The LD50 values of RBS by oral, intraperitoneal or intravenous were 5.27 mg/kg, 3.63 mg/kg and 2.68 mg/kg, respectively. CONCLUSION: RBS has potent antitumor effect, LD50 value of RBS is lower than that of traditional medicine.
    [Abstract] [Full Text] [Related] [New Search]